RE:RE:RE:RE:RE:The Sort1+ PlatformThat's why they ideally need a partner. The other day I listened to a webcast by an oncologist about neuroendocrine cancers. And with this type of cancer the rate of cell division (Ki-67) is talked about a lot. Grade 1 tumors have a Ki-67 of 3% or lower, Grade 2 of 3-20% and grade 3 a Ki-67 above 20%. So the doctor said this grading can be misleading and said that he did two biopsies on the same patient in a short time frame, the first one gave a very high Ki-67 of 70%, and the second one a much lower value at 20%, and he said that such a discrepancy in a same tumor was not uncommon. Advanced cancers are genetically very hetergenous.
Those following the TH1902 story closely from the scientific point of view all saw immunostained biopsy slides for sortilin, with color for cells expressing the receptor and no color on cells not expressing it or expressing it at a very low level. So this is where radionuclides like Lu177 have another advantage over chemo drugs. Lu177 once it is internalized within a cell is not acting only on that cell, the length of its beta radiation allows it to affect 30 layers of cells surrounding the cell in which it is located. So it can affect cells expressing the receptor, but also tumors cells that are not expressing it. So it has a much wider reach to act on tumors than the single cell in which it is internalized. So this is another advantage of radionuclides
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncy.22272
https://jnm.snmjournals.org/content/59/3/459